TheraRadar
Data updated: May 26, 2026

ETHINYL ESTRADIOL AND NORELGESTROMIN (ethinyl estradiol)

Women's Health Approved 2021-02-25

A weekly contraceptive patch that delivers two hormones transdermally for pregnancy prevention. The transdermal delivery method results in greater systemic estrogen exposure compared to oral pills with similar hormone content. Marketed under brand names Ortho Evra and Xulane.

Source: FDA Label • AMNEAL

How ETHINYL ESTRADIOL AND NORELGESTROMIN Works

Hormones absorbed through the skin suppress the monthly maturation of eggs, blocking the ovulation process necessary for conception.

Source: FDA Label
2
Indications
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2021-02-25
Routes
TRANSDERMAL
Dosage Forms
FILM, EXTENDED RELEASE

Companies

Active Ingredient: ETHINYL ESTRADIOL , NORELGESTROMIN

ETHINYL ESTRADIOL AND NORELGESTROMIN Approval History

2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2021 to 2023
Sep 2023 ORIGINAL
Update
Apr 2022 SUPPL
Label · Labeling
Feb 2021 ORIGINAL
Update

What ETHINYL ESTRADIOL AND NORELGESTROMIN Treats

2 FDA approvals

Originally approved for its first indication in 2021 . Covers 2 distinct patient populations.

  • Other (2)

ETHINYL ESTRADIOL AND NORELGESTROMIN Boxed Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Iclevia, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: CIGARETTE SMOKING AND SERIOUS C...

📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 not yet recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ETHINYL ESTRADIOL AND NORELGESTROMIN FDA Label Details

Indications & Usage

Iclevia TM (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. Iclevia is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.

⚠️ BOXED WARNING

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For th...

Track ETHINYL ESTRADIOL AND NORELGESTROMIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.